RenovoRx

RenovoRx RenovoRx (Nasdaq: RNXT) is developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device.

Our CEO, Shaun Bagai, will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on Tuesday,...
06/04/2026

Our CEO, Shaun Bagai, will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on Tuesday, June 23rd at 12:30 P.M. ET. Mr. Bagai will discuss RenovoRx’s record first quarter 2026 revenue, driven by growing demand for RenovoCath® as a standalone drug-delivery device. He will also highlight RenovoCath’s accelerating adoption at high-volume cancer centers and the expanding base of repeat orders. For details: https://bit.ly/4uSjNDT

Leesa Gentry, Chief Clinical Officer of RenovoRx, comments on the Company’s recently granted FDA Orphan Drug Designation...
05/29/2026

Leesa Gentry, Chief Clinical Officer of RenovoRx, comments on the Company’s recently granted FDA Orphan Drug Designation to oxaliplatin for the treatment of pancreatic cancer. This designation further supports the versatility of RenovoRx's novel approach to delivering multiple therapeutic agents directly near the tumor site. https://bit.ly/3RBqdsf

“Receiving a third ODD from the FDA is an important milestone as it provides additional validation of our strategy to bu...
05/28/2026

“Receiving a third ODD from the FDA is an important milestone as it provides additional validation of our strategy to build a multi-agent, targeted, drug-delivery oncology pipeline enabled by our patented RenovoCath device,” said Shaun Bagai, CEO of RenovoRx. The recently granted ODD continues to advance RenovoRx's therapeutic oncology pipeline and provides seven years of market exclusivity.

For more: https://bit.ly/3RBqdsf

RenovoRx announced that the U.S. Food and Drug Administration (FDA) recently granted RenovoRx Orphan Drug Designation (O...
05/28/2026

RenovoRx announced that the U.S. Food and Drug Administration (FDA) recently granted RenovoRx Orphan Drug Designation (ODD) of oxaliplatin for the treatment of pancreatic cancer via intra-arterial drug-delivery. This is RenovoRx’s second ODD in pancreatic cancer, and third designation in total, reflecting the Company’s differentiated approach to targeted intra-arterial drug-delivery using RenovoCath. For details: https://bit.ly/3RBqdsf

Dr. Reza Nazemzadeh comments on the sub-study from the ongoing Phase III TIGeR-PaC clinical trial which supports the TAM...
05/26/2026

Dr. Reza Nazemzadeh comments on the sub-study from the ongoing Phase III TIGeR-PaC clinical trial which supports the TAMP™ platform for targeted intra-arterial delivery of gemcitabine, demonstrating the potential to increase local drug potency and reduce systemic exposure and common side effects. Read more: https://bit.ly/4dKcruy

RenovoRx announced that an abstract from a sub-study of its Phase III TIGeR-PaC clinical trial has been published online...
05/26/2026

RenovoRx announced that an abstract from a sub-study of its Phase III TIGeR-PaC clinical trial has been published online in connection with the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2, 2026. The abstract supports the TAMP platform for targeted intra-arterial delivery of gemcitabine and highlights its potential to increase local drug potency while reducing systemic exposure and common side effects. For more Information: https://bit.ly/4dKcruy

We’re honored to be selected as the “Best New Technology Solution – Drug Delivery” in the 2026 Medtech Breakthrough Awar...
05/20/2026

We’re honored to be selected as the “Best New Technology Solution – Drug Delivery” in the 2026 Medtech Breakthrough Awards.

This recognition underscores the promise of the TAMP™ therapy platform for targeted drug delivery and reflects our team's unwavering dedication to advancing treatment options for patients diagnosed with difficult-to-treat tumors. https://bit.ly/49Twuph

Tune-in today, May 20th at 1:40 PM ET, for RenovoRx CEO Shaun Bagai and CFO Mark Voll's presentation at the AGP Annual H...
05/20/2026

Tune-in today, May 20th at 1:40 PM ET, for RenovoRx CEO Shaun Bagai and CFO Mark Voll's presentation at the AGP Annual Healthcare Company Showcase to learn about the Company’s commercial progress with RenovoCath as a standalone drug-delivery device, including accelerating adoption at high-volume cancer centers and growing repeat orders. For webcast details: https://bit.ly/3PxpQOz

RenovoRx CEO Shaun Bagai and CFO Mark Voll will participate in the Alliance Global Partners Annual Healthcare Company Sh...
05/19/2026

RenovoRx CEO Shaun Bagai and CFO Mark Voll will participate in the Alliance Global Partners Annual Healthcare Company Showcase on Wednesday, May 20th at 1:40 PM ET. They will discuss RenovoRx’s commercial progress, including record first-quarter 2026 revenue from RenovoCath® as a standalone drug-delivery device, accelerating adoption at high-volume cancer centers, and growing repeat orders. They will also highlight the Company’s clinical research programs, such as the ongoing Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer.

For more information: https://bit.ly/3PxpQOz

Active commercial cancer center customers have expanded to 16 with a growing sales pipeline, accelerating adoption of th...
05/15/2026

Active commercial cancer center customers have expanded to 16 with a growing sales pipeline, accelerating adoption of the TAMP™ platform enabled by the RenovoCath® device. Learn more: https://bit.ly/4fn80IF

Address

Mountain View, CA

Website

Alerts

Be the first to know and let us send you an email when RenovoRx posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to RenovoRx:

Shortcuts

Share